The influence of hypomagnesemia (hMg) on overall survival (OS) in a phase III randomized study of cetuximab (CET) plus best supportive care (BSC) versus BSC: NCIC CTG/AGITG CO.17.
Authors:
- C. S. KarapetisCKC. S. Karapetis
- D. TuDTD. Tu
- C. J. O'CallaghanCOC. J. O'Callaghan
- T. J. PriceTPT. J. Price
- N. C. TebbuttNTN. C. Tebbutt
- G. Van HazelGHG. Van Hazel
- J. D. ShapiroJSJ. D. Shapiro
- N. PavlakisNPN. Pavlakis
- P. GibbsPGP. Gibbs
- U. J. Yu Min LeeULU. J. Yu Min Lee
- 20 May 2011
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15_suppl) , 3601